Ensysce Biosciences, Inc. (ENSC)
$0.53+15.22%Close
BUYRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $5M
- Beta
- 0.98
- P/E (TTM)
- -0.16
- Short % float
- 11.66%
- Days to cover
- 3.4
- SI change
- -10.4%
- 1W
- +32.50%
- 1M
- +1.92%
- vs SPY 1W
- +31.34%
- vs SPY 1M
- -1.07%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 4
- GROWTH
- 25
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-426.9%
GROSS100
OP-1087
NET-1084
[VALUATION]
P/E TTM-0.16
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B-7.17
P/FCF-
EV/EBITDA-0.49
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.70
ND/EBITDA-
BETA0.98
Company news
FAQ
- What is LOPJLB’s current signal on ENSC?
- LOPJLB’s latest quantitative signal on Ensysce Biosciences, Inc. (ENSC) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is ENSC in?
- Ensysce Biosciences, Inc. (ENSC) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Ensysce Biosciences, Inc. (ENSC) do?
- Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrug…